Robert Baker, DO
Family Medicine · van Buren, ARNPI 1992793293
Payments from drug & device makers
Across 193 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$500
- AbbVie$356
- Amgen$221
- Pfizer$192
- Johnson & Johnson$179
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$174
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,924100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $500 |
| AbbVie(2 entities) | 32 | $356 |
| Amgen | 13 | $221 |
| Pfizer | 11 | $192 |
| Johnson & Johnson | 12 | $179 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $174 |
| GSK | 10 | $154 |
| Novo Nordisk | 8 | $150 |
| Eisai Inc. | 6 | $123 |
| Lilly USA, LLC | 7 | $101 |
| Merck | 6 | $98 |
| Boehringer Ingelheim | 6 | $90 |
| Mylan Specialty L.p. | 3 | $66 |
| Bayer | 4 | $66 |
| Novartis | 4 | $63 |
| Sunovion Pharmaceuticals Inc. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $40 |
| Amarin Pharma, Inc. | 2 | $38 |
| Abbott | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Scilex Pharmaceuticals Inc. | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| UCB, Inc. | 1 | $20 |
| Exact Sciences | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $12 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $2 |
How this compares
$2,930 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 87 | $100,216 |
| OzempicSemaglutide | 88 | $89,240 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $76,666 |
| JardianceEmpagliflozin | 55 | $54,184 |
| EliquisApixaban | 66 | $45,315 |
| TrulicityDulaglutide | 24 | $31,288 |
| Breo ElliptaFluticasone/Vilanterol | 69 | $26,747 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 917 | $25,702 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $22,677 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $20,491 |
| Repatha SureclickEvolocumab | 26 | $14,429 |
| Repatha SyringeEvolocumab | 23 | $12,611 |
| TrintellixVortioxetine Hydrobromide | 16 | $11,184 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,057 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $8,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $101 | $131,504111 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $154 | $108,650185 claims |
| Novo NordiskOzempic | $150 | $89,24088 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $90 | $68,64783 claims |
| PfizerEliquis | $192 | $45,31566 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $500 | $31,26169 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $40 | $11,18416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in van Buren
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.